Vaxneuvance
Sponsors
GlaxoSmithKline
Conditions
Chickenpox
Phase 3
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
RecruitingNCT06693895
Start: 2024-11-26End: 2026-11-23Target: 750Updated: 2025-01-20
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
RecruitingNCT06740630
Start: 2025-01-10End: 2027-05-13Target: 1840Updated: 2025-03-07
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
RecruitingNCT06806137
Start: 2025-05-15End: 2027-05-03Target: 600Updated: 2025-12-04
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
RecruitingNCT06855160
Start: 2025-04-17End: 2027-02-02Target: 900Updated: 2025-12-04